Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorValenta Pharm JSC

About this trial

Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Voluntary and handwritten informed consent form signed by a healthy volunteer to participate in the study prior to any of the study procedures;

Healthy male and female caucasian volunteers aged 18 to 45 years (inclusive);

Verified diagnosis "healthy" (without abnormal findings in the protocol-defined clinical, laboratory, and instrumental test data);

pH according to hourly pH-metry in the screening period, carried out at least 3 hours after the last meal, is completely in the range from 1 to 3 inclusive throughout the entire astronomical hour of measurement;

Disqualifiers

A history of allergy;

History of drug intolerance to the active and/or excipients included in the study drugs;

History of drug intolerance of or hypersensitivity/allergic reactions to lidocaine, xylocaine or other topical anesthetics which will be used at the trial site for anesthesia during esophagogastroduodenoscopy (EGD) and insertion of the probe for the pH measurements;

Chronic diseases of the circulatory, lymphatic, respiratory, nervous, endocrine, gastrointestinal, musculoskeletal, integumentary, immune, urogenital, and hematopoietic systems;

Trial design

Design model

Crossover

Treatments tested in this trial

  • Antareit

    Drug

    A single dose of T or R drug in each of 2 periods of the study 2 h prior to food intake

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: TR-sequence (T-test drug, R-reference drug)Experimental treatment 1 intervention
Group B: RT-sequenceExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Pharmacodynamics - AUCpH - Area under the curve potential of hydrogen

Area under the pharmacodynamic pH-time curve

Time frame
From 0 to 1 hour (Day 1 and Day 8)
2

Pharmacodynamics - time percentage during which the intragastric pH value will exceed 4.0

PH - potential of hydrogen

Time frame
From 0 to 1 hour (Day 1 and Day 8)
3

Pharmacodynamics- рНmaximum

maximum potential of hydrogen

Time frame
From 0 to 1 hour (Day 1 and Day 8)
4

Pharmacodynamics- рНmin

minimum potential of hydrogen

Time frame
From 0 to 1 hour (Day 1 and Day 8)

Secondary outcomes

1

Safety and Tolerability: adverse event (AE) number and frequency

Number and frequency of adverse events (AEs) or serious AEs (SAEs)

Time frame
From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
2

Safety and Tolerability: serious adverse event (SAE) number and frequency

Number and frequency of serious AEs (SAEs)

Time frame
From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
3

Safety and Tolerability: volunteer complaints

Time frame
From the screening (and signing informed consent form) to Day 15 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 15)
4

Safety and Tolerability: physical examination results

Physical examination will be conducted to identify normal and abnormal physical characteristics of volunteers in accordance with the planned examination and will include an assessment of the Condition of the cardiovascular, respiratory, digestive, endocrine, musculoskeletal, nervous, sensory systems, skin/visible mucous membranes

Time frame
Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 15)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.